Northwestern Mutual Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$147	Sell	40 -411	-91%	-$1.37K	﹤0.01%	3970
2026 Q1	$1.39K	Buy	451 +406	+902%	+$1.57K	﹤0.01%	3688
2025 Q4	$184	Buy	45 +44	+4,400%	+$218	﹤0.01%	3813
2025 Q3	$5	Buy	+1	New	+$5	﹤0.01%	3781
2024 Q4	–	Sell	-5,399	Closed	-$35.6K	–	3845
2024 Q3	$35.6K	Buy	+5,399	New	+$38.7K	﹤0.01%	2277
2022 Q1	–	Sell	-8	Closed	–	–	3359
2021 Q4	$0	Buy	+8	New	+$151	﹤0.01%	3303

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northwestern Mutual Wealth Management's RXRX Position: Q2 2026 in Review

Northwestern Mutual Wealth Management reduced its Recursion Pharmaceuticals (RXRX) stake by 91% in Q2 2026, selling an estimated $1.37K and leaving 40 shares worth $147. The position accounts for ﹤0.01% of the portfolio, ranked #3970.

Northwestern Mutual Wealth Management first reported a position in RXRX in Q4 2021 and has held it in 6 quarters since. The position peaked at $35.6K in Q3 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Northwestern Mutual Wealth Management held 40 shares of Recursion Pharmaceuticals worth $147 as of Q2 2026.
Northwestern Mutual Wealth Management sold 411 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.37K.
Recursion Pharmaceuticals made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #3970 holding.
Northwestern Mutual Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
Northwestern Mutual Wealth Management's Recursion Pharmaceuticals position peaked at $35.6K in Q3 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.